GLPwatch
Tendency of Semaglutide to Induce Gastroparesis: A Case Report.
Cureus · 2024
Last updated 2026-09-01A patient taking semaglutide, a drug used for type 2 diabetes and weight loss, developed gastroparesis, a condition that slows stomach emptying. The patient already had symptoms like bloating and nausea before starting the drug, which may have worsened with semaglutide. Gastrointestinal side effects, including gastroparesis, can occur with this medication.
AI summary of the abstract below.
| Journal | Cureus, 2024 |
|---|---|
| Citations | 21 |
| Relative citation ratio | 4.38 |
| NIH percentile | 91 |
| Molecules | semaglutide |
Abstract
Semaglutide, an agonist of the glucagon-like peptide-1 receptor, is frequently used in the treatment of diabetes mellitus type 2, although, lately, weight loss has additionally become a reason for its use. However, if a patient is already experiencing bloating, nausea, abdominal pain, and discomfort in the abdomen, it is not recommended to use it due to concern about aggravating these symptoms. Although it is often well tolerated, there are occasions when it can have several gastrointestinal side effects. Therefore, we report a case of a patient who started taking semaglutide and later developed gastroparoresis.
Verbatim abstract via PubMed 38371020 ↗
Related research
- Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
- Once-Weekly Semaglutide in Adults with Overweight or Obesity.
- Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes.
- A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis.
- Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes.
- Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
- Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes.
- Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity.